publication date: Jun. 30, 2016
- Jun. 30, 2016
June 2016PDF

 

 

Leukemia and Lymphoma

Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

AbbVie published longer-term follow-up results from three phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: RESONATE, RESONATE-2 and HELIOS.

These data were presented at the annual meeting of the American Society of Clinical Oncology. Imbruvica is jointly developed and commercialized in the U.S. by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech Inc.

“Our clinical data presented at this year’s ASCO from several randomized studies demonstrate solid durability of response with Imbruvica in patients with CLL/SLL with additional follow-up of up to three years,” said Danelle James, head of oncology at Pharmacyclics.

Also:

 

Breast Cancer

Combination of Surgery and Standard Therapy Increases Survival in Stage IV, Study Says

A combination of surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by standard therapies, can add months to patients’ lives when compared with standard therapy alone, according to an international phase III study.

“Our findings will change the standard of care for women newly diagnosed with stage IV breast cancer,” said lead investigator Atilla Soran, clinical professor of surgery at the University of Pittsburgh School of Medicine and breast surgical oncologist with UPMC CancerCenter. “We’ve shown that surgery to remove the primary tumor—either through lumpectomy or mastectomy—followed by standard therapy, is beneficial over no surgery.”

Also:

 

Drugs and Targets

FDA Approves EGFR Companion Diagnostic For Tarceva Therapy

 

Melanoma

 

Soft Tissue Sarcoma

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

 

Multiple Myeloma

Kyprolis, Lenalidomide and Dexamethasone Combination Improves PFS, OS in Phase III

 

NCI CTEP-Approved Trials for the Month of June

Copyright (c) 2017 The Cancer Letter Inc.